Results 141 to 150 of about 1,129 (187)

Effect of Azilsartan on clinical blood pressure reduction compared to other angiotensin receptor blockers: a systematic review and meta-analysis. [PDF]

Ann Med Surg (Lond)
Khan QA, Sharma S, Mulk IU, Li D, Belay NF, Afzal M, Farrukh AM, Asad M, Baqi A, Semakieh B.   +9 more
europepmc   +1 more source

SIMULTANEOUS DETERMINATION OF AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE BY UV SPECTROPHOTOMETRIC METHOD

International Journal of Biology, Pharmacy and Allied Sciences
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Azilsartan Medoxomil: A New Angiotensin Receptor Blocker

Clinical Therapeutics, 2011
Azilsartan medoxomil is an angiotensin receptor blocker, approved on February 25, 2011 by the US Food and Drug Administration (FDA) for hypertension management.The purpose of this study was to review the pharmacology, pharmacokinetics, efficacy, safety profile, and role of azilsartan for hypertension management.Peer-reviewed clinical trials, review ...
Kathy, Zaiken, Judy W M, Cheng
openaire   +4 more sources

Azilsartan Medoxomil/Chlorthalidone: A New Fixed-Dose Combination Antihypertensive

Annals of Pharmacotherapy, 2013
OBJECTIVE To evaluate the efficacy, safety, and clinical utility of the combination product azilsartan medoxomil/chlorthalidone for the treatment of hypertension. DATA SOURCES Articles indexed in PubMed through December 2012 were identified using the MeSH terms azilsartan and chlorthalidone, Edarbyclor, TAK-490, and Edarbi.
Danielle, Pierini, Katherine Vogel, Anderson   +1 more
openaire   +3 more sources

Azilsartan medoxomil, belimumab, and lurasidone hydrochloride

Journal of the American Pharmacists Association, 2011
Antihypertensive agent Azilsartan medoxomil (Edarbi—Takeda) is the eighth angiotensin II receptor blocker (ARB) to be marketed in the United States, joining candesartan cilexetil (Atacand), eprosartan (Teveten), irbesartan (Avapro), losartan (e.g., Cozaar), olmesartan medoxomil (Benicar), telmisartan (Micardis), and valsartan (Diovan).
Daniel A. Hussar, Anokhi Shah
openaire   +1 more source

Azilsartan Medoxomil Capabilities in Arterial Hypertension and Obesity

Kardiologiia, 2016
Arterial hypertension (AH) is one of the most common cardiovascular disease. Angiotensin II (AT II), the hormone of renin-angiotensin-aldosterone system, realizes its negative effects through AT 1 receptors - application point of angiotensin receptor blockers (ARB).
Y A, Vasyuk, E Y, Shupenina, V V, Nesvetov, E A, Nesterova, E I, Golubkova   +4 more
openaire   +2 more sources

Efficacy of azilsartan medoxomil with chlorthalidone in hypertension

Expert Review of Cardiovascular Therapy, 2014
Azilsartan medoxomil (AZL) is the most recently approved angiotensin receptor blocker (ARB) for treating patients with hypertension. A fixed-dose combination product with AZL and the thiazide-like diuretic chlorthalidone (CLD) is now available to treat individuals who require additional blood pressure lowering.
William L, Baker, Stefanie C, Nigro, William B, White   +2 more
openaire   +2 more sources

Azilsartan Medoxomil

Clinical Drug Investigation, 2012
Azilsartan medoxomil (Edarbi®; Ipreziv™) is an orally administered angiotensin II receptor type 1 antagonist (blocker) used in the treatment of adults with essential hypertension. This article reviews data on the clinical efficacy and tolerability of azilsartan medoxomil in adults with essential hypertension and provides a summary of its ...
openaire   +2 more sources